Effect of vaginal estrogen on pessary use

Hendrix SL, Clark A, Nygaard I et al (2002) Pelvic organ prolapse in the women’s health initiative: gravity and gravidity. Am J Obstet Gynecol 186:1160–1166

Jelovsek JE, Maher C, Barber MD (2007) Pelvic organ prolapse. Lancet 369:1027–1038

Cundiff GW, Weidner AC, Visco AG et al (2000) A survey of pessary use by members of the American urogynecologic society. Obstet Gynecol 95:931–935

Clemons JL, Aguilar VC, Tillinghast TA et al (2004) Patient satisfaction and changes in prolapse and urinary symptoms in women who were fitted successfully with a pessary for pelvic organ prolapse. Am J Obstet Gynecol 190:1025–9

Powers K, Lazarou G, Wang A et al (2006) Pessary use in advanced pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct 17:160–164. doi: 10.1007/s00192-005-1311-8

Hanson L-AM, Schulz JA, Flood CG et al (2006) Vaginal pessaries in managing women with pelvic organ prolapse and urinary incontinence: patient characteristics and factors contributing to success. Int Urogynecol J Pelvic Floor Dysfunct 17:155–159

Wu V, Farrell SA, Baskett TF, Flowerdew G (1997) A simplified protocol for pessary management. Obstet Gynecol 90:990–994

Krause M, Wheeler TL, Snyder TE, Richter HE (2009) Local effects of vaginally administered estrogen therapy: a review. J Pelvic Med Surg 15:105–114

Speroff L (2003) Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstet Gynecol 102:823–834

Notelovitz M, Funk S, Nanavati N, Mazzeo M (2002) Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol 99:556–562

Oliver R, Thakar R, Sultan AH (2011) The history and usage of the vaginal pessary: a review. Eur J Obstet Gynecol Reprod Biol 156:125–30

Vandenbroucke JP, Von Elm E, Altman DG et al (2007) Strengthening the reporting of observational epidemiology (STROBE): explanation and elaboration. Epidemiology 18:805–835

Hernán MA, Hernández-díaz S, Werler MM, Mitcheil AA (2002) Causal knowledge as a prerequisite for confounding evaluation : an application to birth defects epidemiology. Am J Epidemiol 155:176–184

Cardozo L, Bachmann G, Mcclish D et al (1998) Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the hormones and urogenital therapy committee. Obstet Gynecol 92:722–727

Bugge C, Ej A, Gopinath D, Reid F (2013) Pessaries (mechanical devices) for pelvic organ prolapse in women. Cochrane Database Syst Rev 2, CD004010

Collins S, Beigi R, Mellen C et al (2015) The effect of pessaries on the vaginal microenvironment. Am J Obstet Gynecol 212:e1–6

Friedman S, Sandhu KS, Wang C et al (2010) Factors influencing long-term pessary use. Int Urogynecol J Pelvic Floor Dysfunct 21:673–678

Kingsberg SA, Wysocki S, Magnus L, Krychman ML (2013) Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal women’s VIews of treatment options for menopausal vaginal changEs) survey. J Sex Med 10:1790–1799

Lindahl SH (2014) Reviewing the options for local estrogen treatment of vaginal atrophy. Int J Womens Health 6:307–312

Rahn DD, Ward RM, Sanses TV et al (2014) Vaginal estrogen use in postmenopausal women with pelvic floor disorders: systematic review and practice guidelines. Int Urogynecol J 26:3–13

Suckling J, Lethaby A, Kennedy R (2006) Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 11, CD001500

Rahn DD, Carberry C, Sanses TV et al (2014) Vaginal estrogen for genitourinary syndrome of menopause. Obstet Gynecol 124:1147–1156